



## **Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference**

February 1, 2024 11:30 AM EST

BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- [Verve Therapeutics](#), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6<sup>th</sup> Annual Biotechnology Conference on Thursday, February 8, 2024 at 11:30 a.m. ET in New York.

A live webcast will be available in the investor section of the company's website at [www.vervetx.com](http://www.vervetx.com). The webcast will be archived for 30 days following the presentation.

### **About Verve Therapeutics**

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company's initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as pharmacologic targets for lowering low-density lipoprotein cholesterol ("LDL-C"), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels.

### **Investor Contact**

Jen Robinson  
Verve Therapeutics, Inc.  
[jrobinson@vervetx.com](mailto:jrobinson@vervetx.com)

### **Media Contact**

Ashlea Kosikowski  
1AB  
[ashlea@1abmedia.com](mailto:ashlea@1abmedia.com)